J. Kuruvilla

发表

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score.

Kyung-Han Lee, R. Kridel, R. Tsang, 2020, Blood advances.

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

M. Shipp, P. Zinzani, P. Armand, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis

V. Kukreti, M. Crump, J. Kuruvilla, 2014, Leukemia & lymphoma.

Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.

L. Sehn, J. Kuruvilla, C. Bellingham, 2015, Clinical lymphoma, myeloma & leukemia.

R. Tsang, M. Pintilie, M. Crump, 2006, Cancer.

Significance of treatment response when managing patients with primary central nervous system lymphoma

W. Mason, F. Moraes, A. Berlin, 2018, Leukemia & lymphoma.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

J. Cerhan, C. Gisselbrecht, E. W. Van Den Neste, 2017, Blood.

Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation.

J. Lipton, J. Kuruvilla, Vikas Gupta, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation.

J. Lipton, E. Atenafu, J. Kuruvilla, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

J. Kuruvilla, C. Bredeson, A. Xenocostas, 2016, Current oncology.

Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume

R. Kridel, R. Tsang, Wei Xu, 2022, American journal of hematology.

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.

T. Panzarella, G. Devins, Stephanie J. Lee, 2016, The Lancet. Oncology.

Myeloablative Allogeneic Stem Cell Transplantation for Non-Hodgkin’s Lymphoma

J. Lipton, J. Kuruvilla, P. Mollee, 2010 .

Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.

G. Pond, R. Tsang, J. Lipton, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2021, Blood advances.

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma

G. Salles, J. Connors, F. Cavalli, 2020, International journal of environmental research and public health.

Relapsed/Refractory Hodgkin Lymphoma

J. Kuruvilla, Semira Sheikh, 2018, HemaSphere.

Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin’s lymphoma resistant to platinum-containing first-line salvage chemotherapy

N. Puig, R. Tsang, C. Massey, 2012, Haematologica.

How I treat relapsed and refractory Hodgkin lymphoma.

M. Crump, J. Kuruvilla, A. Keating, 2011, Blood.

Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma

R. Tsang, E. Atenafu, V. Kukreti, 2017, Leukemia & lymphoma.

Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma

J. Kuruvilla, M. Jain, 2017, Drugs.

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.

N. Johnson, A. Santoro, P. Zinzani, 2021, The Lancet. Oncology.

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†

Bingshu E. Chen, K. Savage, T. Reiman, 2018, Leukemia & lymphoma.

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma

I. Flinn, A. Santoro, P. Hagner, 2022, EJHaem.

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure.

P. Zinzani, P. Armand, J. Kuruvilla, 2020, Blood advances.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

K. Savage, D. Neuberg, G. Pinkus, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

O. Griffith, M. Griffith, B. Costello, 2018, Blood.

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

L. Seymour, J. Lyons, S. Gibson, 2017, Leukemia & lymphoma.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

M. Shipp, P. Zinzani, P. Armand, 2017, Blood.

Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

R. Tsang, M. Pintilie, M. Crump, 2009, Leukemia & lymphoma.

Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume

R. Kridel, R. Tsang, Wei Xu, 2021, American journal of hematology.

Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study.

A. Prica, V. Kukreti, J. Kuruvilla, 2022, Clinical lymphoma, myeloma & leukemia.

Evolving management strategies for lymphomas during the COVID-19 pandemic

Noémie Lang, J. Kuruvilla, N. Lang, 2020, Leukemia & lymphoma.

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

N. Johnson, A. Santoro, P. Zinzani, 2021, Blood advances.

Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.

J. Lipton, A. Viswabandya, R. Kotchetkov, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.

B. Storer, T. Panzarella, M. Aljurf, 2016, Blood.

The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD

J. Lipton, J. Kuruvilla, M. Shanavas, 2014, Bone Marrow Transplantation.

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma

J. Kuruvilla, Semira Sheikh, F. Locke, 2021, EJHaem.

Multiple Single-Nucleotide Polymorphism–Based Risk Model for Clinical Outcomes After Allogeneic Stem-Cell Transplantation, Especially for Acute Graft-Versus-Host Disease

H. Won, J. Lipton, W. Xu, 2012, Transplantation.

Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant

W. Xu, V. Kukreti, M. Crump, 2013, Leukemia & lymphoma.

Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low‐dose acyclovir prophylaxis and pre‐transplant diagnosis of lymphoproliferative disorders

M. Minden, J. Lipton, J. Kuruvilla, 2008, Transplant infectious disease : an official journal of the Transplantation Society.

Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment.

H. Mackay, A. Oza, Lisa I. Wang, 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY

K. Savage, U. Jaeger, M. Shipp, 2021, Hematological Oncology.

Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.

J. Lipton, W. Xu, J. Kuruvilla, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation for diffuse large B cell lymphoma: defining the role of allografts.

J. Kuruvilla, J. Uhm, 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)

J. Kuruvilla, S. Ben-Barouch, 2019, Expert opinion on investigational drugs.

A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)

G. Salles, Sonali M. Smith, J Zhang, 2022, HemaSphere.

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

K. Savage, M. Shipp, A. Santoro, 2016 .

Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients.

M. Minden, Deepali Kumar, A. Humar, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD

J. Lipton, E. Atenafu, J. Kuruvilla, 2015, Bone Marrow Transplantation.

Application of CIBMTR risk score to NIH chronic GVHD at individual centers.

B. Storer, J. Lipton, J. Kuruvilla, 2014, Blood.

Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

J. Lipton, K. Wong, E. Atenafu, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Aplastic anemia following administration of a tumor necrosis factor‐α inhibitor

J. Kuruvilla, L. Vickars, Charles H Li, 2003 .

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

R. Houot, M. Kersten, V. Plaks, 2019, Blood.

Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation.

T. Panzarella, T. Panzarella, M. Crump, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma

N. Puig, Lisa I. Wang, M. Crump, 2013, Leukemia & lymphoma.

Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.

J. Connors, K. Savage, T. Panzarella, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital

R. Tsang, M. Gospodarowicz, A. Sun, 2013, Leukemia & lymphoma.

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma

J. Connors, C. Deng, O. O’Connor, 2018, British journal of haematology.

Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab

R. Tsang, T. Panzarella, V. Kukreti, 2015, Leukemia & lymphoma.

Blood-Based Biomarkers of Cancer-Related Cognitive Impairment in Non-Central Nervous System Cancer: A Scoping Review.

Joaquin A. Anguera, J. Anguera, J. Kuruvilla, 2022, Critical reviews in oncology/hematology.

Prospective assessment of the natural history of positive D-dimer results in persons with acute venous thromboembolism (DVT or PE)

M. Kovacs, J. Kuruvilla, M. Keeney, 2003, Thrombosis and Haemostasis.

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission

J. Lipton, E. Atenafu, J. Kuruvilla, 2015, Bone Marrow Transplantation.

Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy

A. Prica, J. Kuruvilla, A. Vijenthira, 2021, Bone Marrow Transplantation.

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

L. Sehn, S. Dietrich, N. Bartlett, 2021, Blood.

Developing anti-CD19 antibody-based combinations in lymphoma.

J. Kuruvilla, 2020, The Lancet. Oncology.

Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy

L. Sehn, A. Prica, J. Kuruvilla, 2020, Leukemia & lymphoma.

The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma.

J. Kuruvilla, 2016, Blood.

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

J. Connors, C. Deng, O. O’Connor, 2015 .

Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.

J. Lipton, J. Kuruvilla, Vikas Gupta, 2015, Clinical lymphoma, myeloma & leukemia.

Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial

M. Kaminski, J. Connors, I. Flinn, 2018, Blood.

A systematic review of contemporary phase I trials in patients with lymphoma.

A. Stathis, J. Kuruvilla, F. Bertoni, 2022, Critical reviews in oncology/hematology.

Reply to C.s. Tam et Al.

T. Panzarella, J. Kuruvilla, D. Villa, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.

J. Lipton, E. Atenafu, J. Kuruvilla, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of siltuximab in patients with previously treated multicentric Castleman’s disease (MCD).

N. Munshi, A. Dispenzieri, A. Fosså, 2014 .

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

J. Rossi, A. Dispenzieri, A. Fosså, 2020, British journal of haematology.

Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group

M. Pintilie, J. Kuruvilla, S. Lachance, 2010, Bone Marrow Transplantation.

Autologous hematopoietic cell transplantation of mantle cell lymphoma: emerging trends

J. Kuruvilla, Umberto Falcone, 2017, Current opinion in hematology.

Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD

J. Lipton, J. Kuruvilla, Vikas Gupta, 2017, Annals of Hematology.

Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)

R. Bociek, R. Martell, J. Kuruvilla, 2008 .

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

J. Kuruvilla, D. Hogge, Clayton A. Smith, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk of Acute Leukemia Post-Autologous Stem Cell Tranplant (ASCT) for Hodgkin’s Lymphoma (HL) Depends on Choice of Salvage Chemotherapy and Use of Radiation.

R. Tsang, N. Dhani, M. Pintilie, 2007 .

Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation

J. Kuruvilla, D. Hogge, S. Nantel, 2004, Bone Marrow Transplantation.

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.

J. Sancho, U. Jaeger, Xiwen Ma, 2021, Clinical lymphoma, myeloma & leukemia.

G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation

M. Crump, J. Kuruvilla, A. Keating, 2008, Bone Marrow Transplantation.

Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma

A. Prica, M. Crump, J. Kuruvilla, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance.

J. Lipton, W. Xu, J. Kuruvilla, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

J. Byrd, I. Flinn, R. Garzon, 2014 .

Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study

R. Kridel, A. Prica, S. Bhella, 2022, Leukemia & lymphoma.

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

J. Byrd, G. Pond, A. Oza, 2013 .

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

J. Byrd, G. Pond, A. Oza, 2013 .

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

K. Savage, M. Shipp, A. Santoro, 2018, Blood.

M. Minden, J. Lipton, J. Kuruvilla, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: An economic evaluation of the ZUMA-7 trial.

M. Perales, Robert S Blissett, J. Kuruvilla, 2022, Transplantation and cellular therapy.

Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT

T. Panzarella, J. Lipton, J. Kuruvilla, 2013, Bone Marrow Transplantation.

Clinical efficacy of prophylactic strategy of long‐term low‐dose acyclovir for Varicella‐Zoster virus infection after allogeneic peripheral blood stem cell transplantation *

M. Minden, Deepali Kumar, J. Lipton, 2008, Clinical transplantation.

Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor.

J. Kuruvilla, L. Vickars, H. Leitch, 2003, European journal of haematology.

Limited benefit of pentostatin salvage therapy for steroid‐refractory grade III‐IV acute graft‐versus‐host disease

J. Lipton, A. Viswabandya, E. Atenafu, 2013, Clinical transplantation.

Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.

J. Lipton, J. Kuruvilla, Vikas Gupta, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A comparison of two methods of undertaking directly observed therapy in a rural indian setting.

J. Kuruvilla, P. Davies, A. Mathew, 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders.

Sunita Ghosh, J. Preiksaitis, R. Goswami, 2022, Clinical lymphoma, myeloma & leukemia.

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

N. Johnson, A. Santoro, P. Zinzani, 2020, Journal of Clinical Oncology.

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Sonali M. Smith, J Zhang, K. Davis, 2022, Blood advances.

Mycophenolate‐based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative‐related donor stem cell transplantation

J. Lipton, J. Kuruvilla, Vikas Gupta, 2015, American journal of hematology.

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.

G. Pond, K. Pritchard, V. Kukreti, 2016, Clinical lymphoma, myeloma & leukemia.

Impact of intensity of conditioning therapy in patients aged 40–60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation

G. Guyatt, J. Lipton, J. Kuruvilla, 2011, Bone Marrow Transplantation.

Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors

J. Kuruvilla, R. Laister, F. Manji, 2023, Biomolecules.

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193

L. Seymour, J. Lyons, J. Kuruvilla, 2014 .

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

Lillian L. Siu, David Mendelson, Michael J. Pishvaian, 2010, Clinical Cancer Research.

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

Michael L. Wang, I. Flinn, R. Garzon, 2017, Blood.

New Treatment Perspectives in CLL : Using Disease and Patient Characteristics to Optimize Outcomes

L. Sehn, J. Kuruvilla, C. Owen, 2015 .

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group

E. Eisenhauer, Christina R. Lee, W. Walsh, 2011, Leukemia & lymphoma.

An evaluation of pembrolizumab for classical Hodgkin lymphoma

J. Kuruvilla, R. Laister, F. Manji, 2022, Expert review of hematology.

Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.

G. Guyatt, M. Crump, J. Kuruvilla, 2012, Journal of the National Cancer Institute.

A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

T. Panzarella, M. Crump, J. Kuruvilla, 2006, Hematology.

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

R. Gascoyne, R. Siebert, J. Connors, 2009, Blood.

factors associated with survival translocations : the critical MYC and BCL 2 Lymphomas with concurrent

Randy, Steidl, R. Siebert, 2009 .

Treatment of newly diagnosed advanced stage Hodgkin lymphoma.

J. Kuruvilla, J. Uhm, 2012, Blood reviews.

Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

D. Scott, R. Kridel, C. Steidl, 2020, British journal of haematology.

Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.

A. Razak, L. Siu, P. Bedard, 2014, Cancer discovery.

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.

Bingshu E. Chen, M. Federico, V. Kukreti, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A single institution experience of extranodal natural killer/T cell lymphoma of nasal type

R. Tsang, M. Gospodarowicz, M. Pintilie, 2015, Leukemia & lymphoma.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

R. Advani, L. Gordon, J. Connors, 2019, Clinical Cancer Research.

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study*

Bingshu E. Chen, L. Sehn, K. Savage, 2017, Leukemia and Lymphoma.

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.

Bingshu E. Chen, M. Crump, J. Kuruvilla, 2015, Blood.

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

T. Panzarella, G. Devins, Stephanie J. Lee, 2014 .

Impact of comorbidities constituting the hematopoietic cell transplant (HCT)‐comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia

J. Lipton, A. Viswabandya, E. Atenafu, 2018, European journal of haematology.

Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR

J. Lipton, E. Atenafu, J. Kuruvilla, 2013, Bone Marrow Transplantation.

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.

T. Panzarella, G. Devins, Stephanie J. Lee, 2020, The Lancet. Haematology.

Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

R. Kridel, J. Dick, M. Minden, 2021, American journal of hematology.

A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin’s lymphoma weighing ≤70 kg

C. Tzeng, S. Kim, J. Kuruvilla, 2018, Bone Marrow Transplantation.

Early lymphocyte recovery at 28 d post‐transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts

J. Lipton, J. Kuruvilla, Vikas Gupta, 2014, European journal of haematology.

Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2

J. Lipton, E. Atenafu, J. Kuruvilla, 2015, Bone Marrow Transplantation.

Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning.

J. Lipton, Wei Xu, J. Kuruvilla, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma

R. Kridel, A. Prica, M. Crump, 2020, Leukemia & lymphoma.

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Michael L. Wang, I. Flinn, R. Garzon, 2015 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.

J. Connors, K. Savage, T. Panzarella, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

D. Maloney, J. Kuruvilla, G. Cartron, 2022, Experimental Hematology & Oncology.

Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.

J. Sancho, U. Jaeger, Xiwen Ma, 2021, Clinical lymphoma, myeloma & leukemia.

Relapse timing is associated with distinct evolutionary dynamics in DLBCL

Ryan D. Morin, R. Kridel, M. Boyle, 2023, medRxiv.

A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board.

J. Connors, J. Kuruvilla, M. Komolova, 2015, Clinical lymphoma, myeloma & leukemia.

Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma

R. Kridel, A. Prica, V. Kukreti, 2021, Leukemia & lymphoma.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

W. Wilson, V. Seshan, R. Advani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The relationship between absolute lymphocyte count with PFS in patients with Hodgkin's lymphoma undergoing autologous hematopoietic cell transplant

M. Pintilie, M. Crump, J. Kuruvilla, 2008, Bone Marrow Transplantation.

Optimal management of mantle cell lymphoma in the primary setting

J. Kuruvilla, Catherine Tang, 2019, Expert review of hematology.

High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma

N. Puig, M. Pintilie, M. Crump, 2011, Bone Marrow Transplantation.

Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors

R. Tsang, M. Crump, J. Kuruvilla, 2012, Leukemia & lymphoma.

Treatment approaches in relapsed or refractory peripheral T-cell lymphomas

J. Kuruvilla, Cheryl Foster, 2020, F1000Research.

MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.

L. Waldron, R. Gascoyne, L. Sehn, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies

M. Minden, S. Kamel‐Reid, J. Lipton, 2008, Bone Marrow Transplantation.

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.

D. Hedley, J. Lipton, A. Viswabandya, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

D. Maloney, J. Kuruvilla, Yeonhee Kim, 2021, Journal of Hematology & Oncology.

Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy

M. Pintilie, M. Crump, J. Kuruvilla, 2008, Hematology.

ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

M. Kersten, N. Schmitz, P. Riedell, 2018 .

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)

R. Houot, M. Kersten, V. Plaks, 2020 .

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

R. Bociek, J. Paulus, Y. Oki, 2011, The Lancet. Oncology.

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

R. Houot, M. Kersten, V. Plaks, 2021, British journal of haematology.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.

L. Sehn, S. Dietrich, N. Bartlett, 2022, The Lancet. Oncology.

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

P. Zinzani, N. Bartlett, J. Kuruvilla, 2022, Leukemia & lymphoma.

Pembrolizumab for the treatment of diffuse large B-cell lymphoma

J. Kuruvilla, Semira Sheikh, 2019, Expert opinion on biological therapy.

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

R. Kridel, S. Trudel, D. Reece, 2019, Blood.

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL

K. Savage, M. Shipp, K. Kato, 2017 .

Extracorporeal photopheresis in the management of graft-versus-host disease.

J. Kuruvilla, R. B. Rumble, C. Bredeson, 2014, Current oncology.

Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience

J. Lipton, J. Kuruvilla, H. Messner, 2007, Bone Marrow Transplantation.

Impact of comorbidities constituting the HCT-CI score on the outcome of patients undergoing allogeneic HCT for AML.

J. Lipton, A. Viswabandya, E. Atenafu, 2017 .

A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.

S. Kamel‐Reid, J. Lipton, E. Atenafu, 2014, Clinical lymphoma, myeloma & leukemia.

Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.

J. Lipton, J. Kuruvilla, Vikas Gupta, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.

M. Crump, J. Kuruvilla, A. Keating, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning

J. Lipton, E. Atenafu, J. Kuruvilla, 2014, Bone Marrow Transplantation.

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin’s lymphoma

N. Puig, R. Tsang, M. Pintilie, 2010, Haematologica.

Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models

H. Won, J. Lipton, J. Kuruvilla, 2014, Bone Marrow Transplantation.

Pharmacist's Role in Improving Medication Safety for Patients in an Allogeneic Hematopoietic Cell Transplant Ambulatory Clinic.

J. Kuruvilla, H. Messner, J. Seki, 2013, The Canadian Journal of Hospital Pharmacy.

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2019, Blood.

Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma‐type post‐transplant lymphoproliferative disorder

L. Sehn, K. Savage, G. Slack, 2020, British journal of haematology.

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Bingshu E. Chen, M. Federico, V. Kukreti, 2012 .

Standard therapy of advanced Hodgkin lymphoma.

J. Kuruvilla, 2009, Hematology. American Society of Hematology. Education Program.

A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning.

T. Panzarella, J. Lipton, S. Alibhai, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP

A. Prica, J. Kuruvilla, L. Shepherd, 2017 .

Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation

J. Lipton, E. Atenafu, J. Kuruvilla, 2015, Bone Marrow Transplantation.

Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation

J. Lipton, S. Rourke, K. Metcalfe, 2016, Bone Marrow Transplantation.

Gelatin‐Hyaluronan Click‐Crosslinked Cryogels Elucidate Human Macrophage Invasion Behavior

A. McGuigan, M. Shoichet, J. Kuruvilla, 2021, Advanced Functional Materials.

Optimal frontline management of mantle cell lymphoma: can we agree?

J. Kuruvilla, Catherine Tang, 2018, Expert review of hematology.

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

F. Cavalli, M. Ogura, M. Hino, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults

M. Maganti, R. Tsang, M. Gospodarowicz, 2015, British journal of haematology.

Relapsed and refractory aggressive NHL: time for a change.

J. Kuruvilla, S. Gangatharan, Shane Gangatharan, 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

B. Siegel, C. Erlichman, N. Bartlett, 2014 .

Permanent right-to-left shunt is the key factor in managing patent foramen ovale.

J. Kuruvilla, G. Rigatelli, Jack P. Chen, 2011, Journal of the American College of Cardiology.

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma

I. Flinn, A. Santoro, T. Witzig, 2022, EJHaem.

Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review

D. Kelly, J. Kuruvilla, A. P. Ayala, 2018, BMJ Open.

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

J. Sancho, U. Jaeger, G. Follows, 2022, Cancers.

Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*

Bingshu E. Chen, M. Federico, M. Crump, 2017, Leukemia & lymphoma.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

N. Johnson, P. Zinzani, J. Kuruvilla, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Sancho, R. Bouabdallah, J. Shah, 2021, Future oncology.

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.

Ryan D. Morin, D. Scott, J. Connors, 2020, Blood advances.

Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma

R. Tsang, M. Pintilie, M. Crump, 2008, Leukemia & lymphoma.

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

M. Maganti, A. Prica, V. Kukreti, 2019, Leukemia & lymphoma.

Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma

R. Tsang, V. Kukreti, M. Crump, 2018, Bone Marrow Transplantation.

Phase II Study of Mocetinostat ( MGCD 0103 ) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma

R. Bociek, J. Paulus, Y. Oki, 2016 .

Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant.

R. Tsang, M. Gospodarowicz, A. Sun, 2012, International journal of radiation oncology, biology, physics.

Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma

Andreas Engert, Arnold S. Freedman, Martin J. S. Dyer, 2014, British journal of haematology.

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

L. Sehn, S. Dietrich, N. Bartlett, 2022, Blood.

Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation

J. Lipton, S. Rourke, K. Metcalfe, 2019, Bone Marrow Transplantation.

Optimization Of Alemtuzumab Dose For Graft-Versus-Host Disease Prophylaxis For Reduced Intensity Transplantation From Unrelated Donors For Patients With Hematologic Malignancies

S. Kamel‐Reid, J. Lipton, W. Xu, 2009 .

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

M. Shipp, P. Zinzani, P. Armand, 2016 .

Computerized cognitive training in post-treatment hematological cancer survivors: a feasibility study

S. Rourke, E. Atenafu, J. Kuruvilla, 2021, Pilot and Feasibility Studies.

Targeting tumour-associated macrophages in hodgkin lymphoma using engineered extracellular matrix-mimicking cryogels.

M. Shoichet, R. Goswami, R. Al-awar, 2023, Biomaterials.

Pembrolizumab for relapsed or refractory Hodgkin lymphoma - Author's reply.

J. Kuruvilla, 2021, The Lancet. Oncology.

Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study

J. Cerhan, C. Gisselbrecht, M. Crump, 2016 .

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

D. Miklos, C. Gisselbrecht, C. Jacobson, 2017 .

A phase I study of the pan-Bcl2 family inhibitor GX15-070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas.

J. Marshall, L. Siu, J. Kuruvilla, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

J. Sancho, U. Jaeger, Xiwen Ma, 2021, Journal of Hematology & Oncology.

The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes

J. Lipton, J. Kuruvilla, Vikas Gupta, 2014 .

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Bingshu E. Chen, M. Federico, J. Kuruvilla, 2013 .

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

S. Ferrari, S. Carrancio, J. Kuruvilla, 2021, Blood.

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.

N. Johnson, J. Kuruvilla, J. Timmerman, 2022, Journal of Clinical Oncology.

Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.

L. Sehn, S. Ben-Neriah, R. Kridel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

N. Johnson, A. Santoro, P. Zinzani, 2018, Blood.

Incidence and Predictors of Bleomycin Pulmonary Toxicity in Hodgkin Lymphoma (HL) Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD),

R. Tsang, E. Atenafu, V. Kukreti, 2011 .

Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study.

K. Savage, M. Shipp, A. Santoro, 2016 .

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

K. Savage, M. Shipp, A. Santoro, 2018, Blood.

Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1

J. Lipton, A. Viswabandya, J. Kuruvilla, 2017, European journal of haematology.

A Retrospective Study on the Incidence of Rituximab-Related Interstitial Pneumonitis In Patients Undergoing Immunochemotherapy for Non-Hodgkin Lymphoma

R. Tsang, V. Kukreti, M. Crump, 2010 .

Updates in the treatment of mantle cell lymphoma: A Canadian expert framework

J. Kuruvilla, D. Villa, C. Lemieux, 2022, Canadian Hematology Today.

Short and Long Term Efficacy of Autologous Bone Marrow Cells To Support Intensive Chemotherapy in Patients Failing Peripheral Blood Stem Cell Mobilization.

M. Crump, J. Kuruvilla, A. Keating, 2007 .

Immunotherapy in Hodgkin lymphoma

J. Kuruvilla, 2022, Canadian Hematology Today.

Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response

S. Kamel‐Reid, J. Lipton, E. Atenafu, 2014, Leukemia & lymphoma.

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

N. Johnson, J. Kuruvilla, J. Timmerman, 2022, Blood.

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY

N. Johnson, J. Kuruvilla, J. Timmerman, 2022, HemaSphere.

Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

Trevor J Pugh, R. Kridel, J. Dick, 2022, American journal of hematology.

Very late relapse in Hodgkin lymphoma: Characterizing an understudied population.

R. Kridel, A. Prica, V. Kukreti, 2023, Clinical lymphoma, myeloma & leukemia.

HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

K. Savage, U. Jaeger, M. Shipp, 2021 .

Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

J. Lipton, S. Rourke, K. Metcalfe, 2015 .

TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

F. Morschhauser, K. Ardeshna, K. Izutsu, 2023, Hematological Oncology.

Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

R. Bouabdallah, U. Jaeger, Xiwen Ma, 2018, Blood.

NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY

N. Johnson, A. Santoro, P. Zinzani, 2021, Hematological Oncology.

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

N. Johnson, J. Kuruvilla, G. Gritti, 2023, Blood advances.

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

M. Shipp, P. Zinzani, P. Armand, 2016 .

Evaluation of Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnosis Clinic.

R. Kridel, J. Delabie, M. Maganti, 2019, Journal of oncology practice.

Addition of Rituximab to CHOP Is an Attractive Strategy as Primary Therapy for Diffuse Large B Cell Lymphoma (DLBCL) in Patients Age <60 Years: An Economic Analysis.

M. Crump, J. Kuruvilla, A. Keating, 2004 .

Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma

M. Crump, J. Kuruvilla, A. Keating, 2008 .

Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma

M. Dyer, A. Freedman, D. Heo, 2014, British journal of haematology.

Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation.

J. Lipton, J. Kuruvilla, Vikas Gupta, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada

J. Kuruvilla, E. Ewara, M. Eberg, 2023, Current oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective assessment of the natural history of positive D-dimer results in persons with acute venous thromboembolism (DVT or PE).

M. Kovacs, J. Kuruvilla, M. Keeney, 2003, Thrombosis and haemostasis.

Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.

J. Lipton, J. Kuruvilla, Vikas Gupta, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

O. Griffith, M. Griffith, B. Costello, 2018, Blood.

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Bingshu E. Chen, M. Federico, M. Crump, 2014 .

Targeted therapy in mediastinal gray zone lymphoma.

J. Kuruvilla, 2023, Blood.

Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials

J. Kuruvilla, D. Hodgson, K. Hueniken, 2023, Leukemia & lymphoma.

Second Cancers after Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma (NHL).

R. Tsang, M. Pintilie, M. Crump, 2007 .

The Influence of Immunodeficiency, Disease Features and Patient Characteristics on Survival in Plasmablastic Lymphoma.

D. Painter, L. Sehn, S. Montoto, 2023, Blood.

Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.

J. Cerhan, C. Gisselbrecht, M. Crump, 2016 .